Trastuzumab (trastuzumab)

Trastuzumab is approved for: Adjuvant treatment of HER2-overexpressing node-positive or node-negative (ER/PR-negative or with one high-risk feature) breast cancer; Metastatic HER2-overexpressing breast cancer, as part of a treatment regimen; HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, in combination with cisplatin and capecitabine or 5-fluorouracil, in patients who have not received prior treatment for metastatic disease. It is a trastuzumab (HER2/neu receptor antagonist — recombinant humanized IgG1 monoclonal antibody; a biologic, regulated as a biosimilar), originally marketed as Herceptin (India: Herclon and Biceltis) by Genentech, Inc. / F. Hoffmann-La Roche Ltd.

Trastuzumab (HER2/neu receptor antagonist — recombinant humanized IgG1 monoclonal antibody; a biologic, regulated as a biosimilar (not a generic) when copied, originally Herceptin (India: Herclon and Biceltis) by Genentech, Inc. / F. Hoffmann-La Roche Ltd) Trastuzumab attaches to the HER2 protein on the surface of cancer cells. This blocks the growth signal the cancer cell relies on, and also signals the body's immune cells to destroy the cancer cell. Intravenous infusion only; do not give as an IV push or bolus. Adjuvant breast cancer (52 weeks total): during and following paclitaxel, docetaxel or docetaxel/carboplatin — loading dose 4 mg/kg over 90 minutes then 2 mg/kg weekly, or loading dose 8 mg/kg then 6 mg/kg every 3 weeks; as a single agent after anthracycline-based chemotherapy — 8 mg/kg loading then 6 mg/kg every 3 weeks. Metastatic br

Trastuzumab is a monoclonal antibody (a biologic), so copies are regulated as BIOSIMILARS, not generics — small-molecule bioequivalence limits (AUC/Cmax within 80-125%) are not applicable. Biosimilar approval requires a stepwise, head-to-head comparability exercise against the reference product: comprehensive analytical/structural and functional (potency) similarity testing, a comparative pharmacokinetic study, and a comparative immunogenicity assessment of anti-drug antibodies, with a comparative efficacy trial required unless biosimilarity can be established from the remainder of the package. WHO guidance explicitly defines a head-to-head comparison of the biosimilar against the reference product as a direct comparison and states that comparison based on historical data is not acceptable; immunogenicity assessment in humans is normally a core part of the clinical comparability package. For trastuzumab, Phase III head-to-head trials have been performed, e.g. the HERITAGE study demonstrated equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer with final overall survival analysis, and a systematic review found no significant differences compared with the reference product in the trials leading to EMA or FDA approval. FDA's June 2024 draft guidance removed the expectation for switching studies for interchangeability, and no trastuzumab product is currently FDA-approved as interchangeable. Indian 'similar biologics' (Canmab, Hertraz, Vivitra, Eleftha) were approved under CDSCO/Indian guidelines with analytical similarity, comparative PK/PD and immunogenicity data; regulators in some ASEAN markets (e.g. NPRA Malaysia) accept such products as interchangeable for prescribing but prohibit automatic substitution and require prescribing by brand name for traceability. Manufacturers supplying trastuzumab generic versions include Aristopharma Ltd., Beacon Pharmaceuticals PLC, Beximco Pharmaceuticals Ltd., Biocon Biologics, Celltrion Inc., Drug International Ltd., Healthcare Pharmaceuticals Ltd., Incepta Pharmaceuticals Ltd.. Brands registered in Bangladesh include Herceptin, Hertin, Herzuma, Ogivri, Tazumab, Trastunix.

Trastuzumab (HER2/neu receptor antagonist — recombinant humanized IgG1 monoclonal antibody; a biologic, regulated as a biosimilar (not a generic) when copied, originally Herceptin (India: Herclon and Biceltis) by Genentech, Inc. / F. Hoffmann-La Roche Ltd) Trastuzumab attaches to the HER2 protein on the surface of cancer cells. This blocks the growth signal the cancer cell relies on, and also signals the body's immune cells to destroy the cancer cell. Intravenous infusion only; do not give as an IV push or bolus. Adjuvant breast cancer (52 weeks total): during and following paclitaxel, docetaxel or docetaxel/carboplatin — loading dose 4 mg/kg over 90 minutes then 2 mg/kg weekly, or loading dose 8 mg/kg then 6 mg/kg every 3 weeks; as a single agent after anthracycline-based chemotherapy — 8 mg/kg loading then 6 mg/kg every 3 weeks. Metastatic br

Trastuzumab (HER2/neu receptor antagonist — recombinant humanized IgG1 monoclonal antibody; a biologic, regulated as a biosimilar (not a generic) when copied, originally Herceptin (India: Herclon and Biceltis) by Genentech, Inc. / F. Hoffmann-La Roche Ltd) Trastuzumab attaches to the HER2 protein on the surface of cancer cells. This blocks the growth signal the cancer cell relies on, and also signals the body's immune cells to destroy the cancer cell. Intravenous infusion only; do not give as an IV push or bolus. Adjuvant breast cancer (52 weeks total): during and following paclitaxel, docetaxel or docetaxel/carboplatin — loading dose 4 mg/kg over 90 minutes then 2 mg/kg weekly, or loading dose 8 mg/kg then 6 mg/kg every 3 weeks; as a single agent after anthracycline-based chemotherapy — 8 mg/kg loading then 6 mg/kg every 3 weeks. Metastatic br

Elimination half-life: Approximately 28 days (the EU product information cites approximately 28-38 days); trastuzumab may persist in the circulation for up to 27 weeks after stopping treatment.. Dosing intervals are designed around this, which is why most regimens are once or twice daily.

Storage: Store vials refrigerated at 2-8°C (36-46°F) before reconstitution; do not freeze, and do not use beyond the expiration date. A vial reconstituted with the supplied bacteriostatic water for injection (BWFI) is stable for 28 days when stored refrigerated at 2-8°C. The current 150 mg single-dose vial is reconstituted with 7.4 mL Sterile Water for Injection without preservative and must be used immediately, with any unused portion discarded. The diluted solution for infusion in 0.9% Sodium Chloride Injection should be stored at 2-8°C for no more than 24 hours before use. Keep the product in its original packaging and check the expiry date printed on the pack.

Trastuzumab is a monoclonal antibody (a biologic), so copies are regulated as BIOSIMILARS, not generics — small-molecule bioequivalence limits (AUC/Cmax within 80-125%) are not applicable. Biosimilar approval requires a stepwise, head-to-head comparability exercise against the reference product: comprehensive analytical/structural and functional (potency) similarity testing, a comparative pharmacokinetic study, and a comparative immunogenicity assessment of anti-drug antibodies, with a comparative efficacy trial required unless biosimilarity can be established from the remainder of the package. WHO guidance explicitly defines a head-to-head comparison of the biosimilar against the reference product as a direct comparison and states that comparison based on historical data is not acceptable; immunogenicity assessment in humans is normally a core part of the clinical comparability package. For trastuzumab, Phase III head-to-head trials have been performed, e.g. the HERITAGE study demonstrated equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer with final overall survival analysis, and a systematic review found no significant differences compared with the reference product in the trials leading to EMA or FDA approval. FDA's June 2024 draft guidance removed the expectation for switching studies for interchangeability, and no trastuzumab product is currently FDA-approved as interchangeable. Indian 'similar biologics' (Canmab, Hertraz, Vivitra, Eleftha) were approved under CDSCO/Indian guidelines with analytical similarity, comparative PK/PD and immunogenicity data; regulators in some ASEAN markets (e.g. NPRA Malaysia) accept such products as interchangeable for prescribing but prohibit automatic substitution and require prescribing by brand name for traceability. Manufacturers supplying trastuzumab generic versions include Aristopharma Ltd., Beacon Pharmaceuticals PLC, Beximco Pharmaceuticals Ltd., Biocon Biologics, Celltrion Inc., Drug International Ltd., Healthcare Pharmaceuticals Ltd., Incepta Pharmaceuticals Ltd.. Brands registered in Bangladesh include Herceptin, Hertin, Herzuma, Ogivri, Tazumab, Trastunix.

Bangladesh unit prices for trastuzumab are not published per unit; the registry lists pack prices only. Prices move with pack size, pharmacy and the exchange rate — confirm current stock and price with a licensed importer before ordering.

Trastuzumab is a monoclonal antibody (a biologic), so copies are regulated as BIOSIMILARS, not generics — small-molecule bioequivalence limits (AUC/Cmax within 80-125%) are not applicable. Biosimilar approval requires a stepwise, head-to-head comparability exercise against the reference product: comprehensive analytical/structural and functional (potency) similarity testing, a comparative pharmacokinetic study, and a comparative immunogenicity assessment of anti-drug antibodies, with a comparative efficacy trial required unless biosimilarity can be established from the remainder of the package. WHO guidance explicitly defines a head-to-head comparison of the biosimilar against the reference product as a direct comparison and states that comparison based on historical data is not acceptable; immunogenicity assessment in humans is normally a core part of the clinical comparability package. For trastuzumab, Phase III head-to-head trials have been performed, e.g. the HERITAGE study demonstrated equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer with final overall survival analysis, and a systematic review found no significant differences compared with the reference product in the trials leading to EMA or FDA approval. FDA's June 2024 draft guidance removed the expectation for switching studies for interchangeability, and no trastuzumab product is currently FDA-approved as interchangeable. Indian 'similar biologics' (Canmab, Hertraz, Vivitra, Eleftha) were approved under CDSCO/Indian guidelines with analytical similarity, comparative PK/PD and immunogenicity data; regulators in some ASEAN markets (e.g. NPRA Malaysia) accept such products as interchangeable for prescribing but prohibit automatic substitution and require prescribing by brand name for traceability. Manufacturers supplying trastuzumab generic versions include Aristopharma Ltd., Beacon Pharmaceuticals PLC, Beximco Pharmaceuticals Ltd., Biocon Biologics, Celltrion Inc., Drug International Ltd., Healthcare Pharmaceuticals Ltd., Incepta Pharmaceuticals Ltd.. Brands registered in Bangladesh include Herceptin, Hertin, Herzuma, Ogivri, Tazumab, Trastunix.